Marzia Bianchi

Marzia Bianchi

Auto-generated profile, based on publicly available information

Marzia Bianchi

Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, PU, Italy

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2016 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
Sara BiagiottiSara Biagiotti
Sara Biagiotti
MMMichele Menotta
Michele Menotta
SOSara Orazi
Sara Orazi
CSChiara Spapperi
Chiara Spapperi
SBSerena Brundu
Serena Brundu
Mauro MagnaniMauro Magnani
Mauro Magnani
Ataxia telangiectasia (A‐T) is a rare incurable neurodegenerative disease caused by biallelic mutations in the gene for ataxia‐telangiectasia mutated (ATM). The lack of a functional ATM kinase leads to a pleiotropic phenotype, and oxidative stress is considered to have a crucial role in the complex physiopathology. Recently, steroids have been shown to reduce the neurological symptoms of the disease, although the molecular mechanism of this effect is largely unknown. In the present study, we have demonstrated that dexamethasone treatment of A‐T lymphoblastoid cells increases the content of two of the most abundant antioxidants [glutathione (GSH) and NADPH] by up to 30%. Dexamethasone promoted the nuclear accumulation of the transcription factor nuclear factor (erythroid‐derived 2)‐like 2 to drive expression of antioxidant pathways involved in GSH synthesis and NADPH production. The latter effect was via glucose 6‐phosphate dehydrogenase activation, as confirmed by increased enzyme activity and enhancement of the pentose phosphate pathway rate. This evidence indicates that glucocorticoids are able to potentiate antioxidant defenses to counteract oxidative stress in ataxia telangiectasia, and also reveals an unexpected role for dexamethasone in redox homeostasis and cellular antioxidant activity.

31 October 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TMTomas Di Mambro
Tomas Di Mambro
TVTania Vanzolini
Tania Vanzolini
MBMarzia Bianchi
Marzia Bianchi
RCRita Crinelli
Rita Crinelli
BCBarbara Canonico
Barbara Canonico
Mauro MagnaniMauro Magnani
Mauro Magnani
The resistance and the birth of new intrinsic and multidrug-resistant pathogenic species likeC.aurisis creating great concern in the antifungal world. Given the limited drug arsenal and the lack of effectiveness of the available compounds, there is an urgent need for innovative approaches. The murine mAb 2G8 was humanized and engineeredin silicoto develop a single-chain fragment variable (hscFv) antibody against β-1,3-glucans which was then expressed inE.coli. Among the recombinant proteins developed, a soluble candidate with high stability and affinity was obtained. This selected protein is VL-linker-VH oriented, and it is characterized by the presence of two ubiquitin monomers at the N-terminus and a His tag at the C-terminus. This construct, Ub2-hscFv-His, guaranteed stability, solubility, efficient purification and satisfactory recovery of the recombinant product. HscFv can bind β-1,3-glucans both as coated antigens and onC.aurisandC.albicanscells similarly to its murine parental and showed long stability and retention of binding ability when stored at 4°, -20° and -80° C. Furthermore, it was efficient in enhancing the antifungal activity of drugs caspofungin and amphotericin B againstC.auris. The use of biological drugs as antifungals is limited; here we present a promising hscFv which has the potential to be useful in combination with currently available antifungal drugs.

22 February 2022 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
MBMarzia Bianchi
Marzia Bianchi
LRLuigia Rossi
Luigia Rossi
FPFrancesca Pierigè
Francesca Pierigè
PAPietro De Angeli
Pietro De Angeli
MAMattia Paolo Aliano
Mattia Paolo Aliano
Mauro MagnaniMauro Magnani
Mauro Magnani
Here we report, for the first time, the engineering of human red blood cells (RBCs) with an entire metabolic pathway as a potential strategy to treat patients with guanidinoacetate methyltransferase (GAMT) deficiency, capable of reducing the high toxic levels of guanidinoacetate acid (GAA) and restoring proper creatine levels in blood and tissues. We first produced a recombinant form of native human GAMT without any tags to encapsulate into RBCs. Due to the poor solubility and stability features of the recombinant enzyme, both bioinformatics studies and extensive optimization work were performed to select a mutant GAMT enzyme, where only four critical residues were replaced, as a lead candidate. However, GAMT-loaded RBCs were ineffective in GAA consumption and creatine production because of the limiting intra-erythrocytic S-adenosyl methionine (SAM) content unable to support GAMT activity. Therefore, a recombinant form of human methionine adenosyl transferase (MAT) was developed. RBCs co-entrapped with both GAMT and MAT enzymes performed, in vitro, as a competent cellular bioreactor to remove GAA and produce creatine, fueled by physiological concentrations of methionine and the ATP generated by glycolysis. Our results highlight that metabolic engineering of RBCs is possible and represents proof of concept for the design of novel therapeutic approaches.

1 August 1994 in Molecular Brain Research
Verified
Journal Article
Closed access
MCMauro Cimino
Mauro Cimino
PMPietro Marini
Pietro Marini
SCSilvia Colombo
Silvia Colombo
FCFlaminio Cattabeni
Flaminio Cattabeni
MBMarzia Bianchi
Marzia Bianchi
Mauro MagnaniMauro Magnani
Mauro Magnani

9 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
Francesca MonittolaFrancesca Monittola
Francesca Monittola
EPElena Perla
Elena Perla
DLDebora Libetti
Debora Libetti
AAAntonella Antonelli
Antonella Antonelli
Laura GraciottiLaura Graciotti
Laura Graciotti
MBMichela Bruschi
Michela Bruschi
Phenylketonuria (PKU) is a genetic metabolic disorder caused by the lack of functional phenylalanine hydroxylase (PAH). Elevated levels of phenylalanine (Phe) are known to be neurotoxic; however, the molecular mechanisms underlying Phe’s effects remain elusive. This study investigates the impact of PKU on proteostasis, redox balance, and metabolism in BTBR PAH enu2 mice, a severe disease animal model. Combined proteomics and metabolomics revealed impaired redox homeostasis in the brain and disrupted mitochondrial energy metabolism (ATP and TCA intermediates). The dysregulation was further supported by decreased levels of ATP, reduced glutathione (GSH), cysteine, and reduced catalase activity. Western blot analyses revealed substantial remodeling of protein degradation systems: the 19S regulatory (Rpt1) subunit and 26S proteasome content and activity were significantly increased, and ubiquitinated protein levels were elevated, indicating protein turnover and activation of the ubiquitin-proteasome system. Autophagy was also activated, as evidenced by a reduced LC3-II/LC3-I ratio, decreased p62 levels, unchanged ATG5 levels, and increased HSPA8 protein expression. By contrast, UPR markers remained stable despite an increase in the oxidized-to-reduced PDI ratio, suggesting a localized shift without activation of a full ER stress response. In parallel, systemic alterations were assessed in whole blood. Indeed, GSH, cysteine, ATP and ADP were decreased in PKU, whereas NADPH increased. These changes were accompanied by reduced activities of GSH reductase and GSH peroxidase, thereby confirming metabolic and redox disruption. Collectively, these findings indicate that PKU is associated with activation of protein degradation pathways as an adaptive response to cellular stress combined with redox imbalance and energy dysregulation. Highlights: - Proteasome complex levels and activity were upregulated in PAH enu2 mouse brains - Autophagy was also enhanced in PAH enu2 mouse brains - Despite increased PDI oxidation, the Unfolded Protein Response was not activated - Redox and energy metabolism were disrupted in both brain and blood